Strategies for the development of conotoxins as new therapeutic leads

Citations of this article
Mendeley users who have this article in their library.


Peptide toxins typically bind to their target ion channels or receptors with high potency and selectivity, making them attractive leads for therapeutic development. In some cases the native peptide as it is found in the venom from which it originates can be used directly, but in many instances it is desirable to truncate and/or stabilize the peptide to improve its therapeutic properties. A complementary strategy is to display the key residues that make up the pharmacophore of the peptide toxin on a non-peptidic scaffold, thereby creating a peptidomimetic. This review exemplifies these approaches with peptide toxins from marine organisms, with a particular focus on conotoxins. © 1996-2013 MDPI AG.




Brady, R. M., Baell, J. B., & Norton, R. S. (2013, July). Strategies for the development of conotoxins as new therapeutic leads. Marine Drugs.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free